Working with the WHO and Doctors Without Borders, Eli Lilly is leading the Lilly MDR-TB partnership to address the expanding crisis of multi-drug resistant tuberculosis (MDR-TB). MDR-TB is a type of tuberculosis that often develops in patients who do not complete the proper treatment for TB and failure to contain MDR-TB could result in the creation of a new, even more deadly strain of the disease. The goal of this initiative is to train enough health personnel and increase the supply of critical drugs needed to treat MDR-TB to meet the treatment goal of 20,000 patients annually by 2010, as set by the WHO. Eli Lilly is for this purpose dealing with all aspects of the MDR-TB problem, from drug supply to treatment and surveillance to evaluation by for instance distributing two critical anti-TB drugs for treatment of MDR-TB at a fraction of production cost. In 2002 Eli Lilly extended for two more years its commitment with the WHO, doubling the previous quantity of medicine supplied. Through the WHO Green Light Committee, Eli Lilly has been an active participant in the treatment of thousands of MDR-TB patients globally, including Peru, Russia and the Philippines. As MDR-TB continues to rise at an alarming rate, Eli Lilly is working with various partners to explore ways to further extend patient coverage.